Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine)

N/A

Report date: 2025/06/26 20:00:07

Base Information

Drug NameAnti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-BCMAAnti-CD70T lymphocyte replacements

TargetsB-cell maturation proteinCD70 antigen

Therapy Area/IndicationsLupus Erythematosus, SystemicNephrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesThe Children'S Hospital, Zhejiang University School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesThe Children'S Hospital, Zhejiang University School Of Medicine

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, SystemicNephrosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A